Results 1 to 10 of about 172,684 (356)
Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy [PDF]
Haematologica, 2016 Due to the lack of specificity for tumor antigens, allogeneic T-cell therapy is associated with graft-versus-host disease. Enhancing the anti-tumor specificity while reducing the graft-versus-host disease risk of allogeneic T cells has remained a ...
Angelika Holler +9 more
doaj +5 more sources
Improved survival after acute graft-versus-host disease diagnosis in the modern era [PDF]
Haematologica, 2017 A cute graft-versus-host disease remains a major threat to a successful outcome after allogeneic hematopoietic cell transplantation. While improvements in treatment and supportive care have occurred, it is unknown whether these advances have resulted in ...
Hanna J. Khoury +46 more
doaj +3 more sources
PLoS ONE, 2021 Graft-versus-host disease is a major complication after allogeneic hematopoietic stem cell transplantation for hematological malignancies. Immunosuppressive drugs, such as anti-thymocyte globulin, alemtuzumab, and post-transplant cyclophosphamide, have ...
Kiyomi Mashima +17 more
doaj +1 more source
Frontiers in Immunology, 2020 Chronic graft-versus-host-disease (cGVHD) is the leading cause of late non-relapse mortality after allogeneic hematopoietic stem cell transplantation(HSCT). There is no standard therapy for patients refractory or dependent to corticosteroid treatment. We
Liren Qian +4 more
doaj +1 more source
Cutaneous graft-versus-host disease after hematopoietic stem cell transplant - a review [PDF]
Anais Brasileiros de Dermatologia, 2016 Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplants (allo-HSCT) associated with significant morbidity and mortality. The earliest and most common manifestation is cutaneous graft-versus-host disease.
Cesar Daniel Villarreal Villarreal +3 more
doaj +1 more source
Ocular graft-versus-host disease: An update on immune pathogenesis and therapies
Medicina Universitaria, 2022 Hematopoietic stem cell transplantation (HSCT) is a treatment option for hematological and non-hematological diseases that do not respond to conventional treatments.
Samantha P. Peña-Lozano +3 more
doaj +1 more source
Patient-reported outcomes and health status associated with chronic graft-versus-host disease
Haematologica, 2018 Chronic graft-versus-host disease occurs in 20–50% of allogeneic hematopoietic cell transplant survivors. We surveyed patients about their quality of life, symptoms, health status, comorbid conditions and medications.
Stephanie J. Lee +8 more
doaj +1 more source
SAGE Open Medical Case Reports, 2022 Graft versus host disease after solid organ transplantation is very rare. This article reports a case of graft versus host disease after liver transplantation following targeted therapy and radiotherapy for the treatment of hepatocellular carcinoma.
Zijun Chen +14 more
doaj +1 more source
Haematologica, 2018 Upper gastrointestinal acute graft-versus-host disease is reported in approximately 30% of hematopoietic stem cell transplant recipients developing acute graft-versus-host disease.
Sarah Nikiforow +28 more
doaj +1 more source
B-cell involvement in chronic graft-versus-host disease
Haematologica, 2008 Chronic graft-versus-host disease is a serious complication in long-term survivors of allogeneic hematopoietic stem cell transplantation, with several organ systems affected.
Rick Kapur +2 more
doaj +1 more source